Feed TSHA
TS

Taysha Gene Therapies, Inc.

TSHA · NASDAQ

$5.01 +0.20% (+$0.01)
1M -19.32%
Market Cap $1.60B
P/E Ratio -
Div. Yield -
ROE 56.19%
Piotroski F-Score Weak
2/9
Valuation
24 /100
Expensive
P/B 4.14x
P/S 292.16x
EV/FFO N/A
Growth
100 /100
Growing
Book val. growth 538.42%
Rev. growth 57.49%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 2,728.04%
Op. margin 2,792.32%
FCF margin 2,471.69%
Quality
0 /100
Poor
ROE 56.19%
ROA 31.81%
Asset turnover 0.01x
Debt
69 /100
Low
Current ratio 17.76x
Int. coverage -3,572.67x
Debt/Equity 0.14x
Stability
34 /100
Moderate
Rev. volatility 308.74%
EPS volatility 36.87%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about TSHA
Online

About the company

Taysha Gene Therapies, Inc. (TSHA) is a biotechnology company focused on the development of advanced gene therapies for the treatment of rare genetic diseases. The company aims to utilize adeno-associated viruses (AAV) to deliver healthy genes into patient cells, with the goal of correcting genetic defects and providing long-term therapeutic effects. Taysha Gene Therapies targets diseases that cause significant impairment to patients and lack effective treatments. Their research and development in the field of gene therapy offer hope to many individuals and have the potential to change the course of these severe diseases. Investors who track innovations in gene therapy and have an interest in treating rare genetic disorders may see potential in Taysha Gene Therapies, Inc. (TSHA) shares for significant improvement in patients' lives and the growth of this company.

Sector

Healthcare

Industry

Biotechnology

CEO

Sean Nolan

Employees

99

Headquarters

Dallas

Upcoming events

03 NOV

Earnings

Upcoming earnings report

49d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.